SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling
Cardiovascular Diabetology · 2024
DOI: 10.1186/s12933-024-02491-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Diabetology, 2024. Verfasst von Sven O Göpel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Global Patient Safety BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden. Sven.gopel@astrazeneca.com. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Glucagon, Signal Transduction, Glucosides. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Background
SGLT2 inhibitors, a T2DM medication to lower blood glucose, markedly improve cardiovascular outcomes but the underlying mechanism(s) are not fully understood. SGLT2i’s produce a unique metabolic pattern by lowering blood glucose without increasing insulin while increasing ketone body and glucagon levels and reducing body weight. We tested if glucagon signaling contributes to SGLT2i induced improvement in CV function.
Methods
Cardiac contractility and coronary flow velocity reserve (CFVR) were monitored in ob/ob mice and rhesus monkeys with metabolic syndrome using echocardiography. Metabolic status was characterized by measuring blood ketone levels, glucose tolerance during glucose challenge and Arg and ADMA levels were measured. Baysian models were developed to analyse the data.
Results
Dapagliflozin improved CFVR and contractility, co-application of a glucagon receptor inhibitor (GcgRi) blunted the effect on CFVR but not contractility. Dapagliflozin increased the Arg/ADMA ratio and ketone levels and co-treatment with GcgRi blunted only the Dapagliflozin induced increase in Arg/ADMA ratio but not ketone levels.
Conclusions
Since GcgRi co-treatment only reduced the Arg/ADMA increase we hypothesize that dapagliflozin via a glucagon-signaling dependent pathway improves vascular function through the NO-signaling pathway leading to improved vascular function. Increase in ketone levels might be a contributing factor in SGLT2i induced contractility increase and does not require glucagon signaling. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Patient Safety BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden. Sven.gopel@astrazeneca.com.
- Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- College of Future Technology, Peking University, Beijing, 100871, China.
- Data Sciences and Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
- Imperial College London, School of Public Health, Department of Epidemiology and Biostatistics, London, United Kingdom.
- Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Förderung
- AstraZeneca
Zitieren
APA
Göpel, S. O., Adingupu, D., Wang, J., Semenova, E., Behrendt, M., Jansson-Löfmark, R., Ahlström, C., Jönsson-Rylander, A. C., Gopaul, V. S., Esterline, R., Gan, L. M., & Xiao, R. P. (2024). SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-024-02491-w
Vancouver
Göpel SO, Adingupu D, Wang J, Semenova E, Behrendt M, Jansson-Löfmark R, et al. SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling. Cardiovascular Diabetology. 2024. doi:10.1186/s12933-024-02491-w
BibTeX
@article{Gpel2024,
author = {Göpel, Sven O and Adingupu, Damilola and Wang, Jue and Semenova, Elizaveta and Behrendt, Margareta and Jansson-Löfmark, Rasmus and Ahlström, Christine and Jönsson-Rylander, Ann-Cathrine and Gopaul, V Sashi and Esterline, Russell and Gan, Li-Ming and Xiao, Rui-Ping},
title = {SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling},
journal = {Cardiovascular Diabetology},
year = {2024},
doi = {10.1186/s12933-024-02491-w}
}
EUVIMED